Experimental asthma drug briquilimab fails to reach Late-Stage testing

NCT ID NCT06592768

Terminated Disease control Sponsor: Jasper Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 1 trial tested a single dose of briquilimab in 17 adults with mild-to-moderate allergic asthma to see if it was safe and could reduce asthma attacks triggered by allergens. The study was terminated early, meaning it did not continue as planned. The main goal was to check for side effects and measure lung function after an allergen challenge.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: briquilimab (also called JSP191)
What this could lead to: If successful, this could point toward a new treatment option for allergic asthma by targeting the underlying immune response.
What could go wrong: This was a very early, small Phase 1 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma allergic disease asthma bronchial disorder Chronic Disease Hypersensitivity, Immediate immune system disorder lung disorder obstructive lung disease Respiratory Hypersensitivity respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIC ASTHMA

Contacts and locations

Locations

McMaster University

Hamilton, Ontario, L8N 3Z5, Canada
University of Alberta

Edmonton, Alberta, T6G 2R3, Canada
University of British Columbia

Vancouver, British Columbia, V6T 1Z4, Canada
University of Calgary

Calgary, Alberta, T2N 1N4, Canada
University of Laval

Québec, Quebec, G1V 0A6, Canada
University of Saskatchewan

Saskatoon, Saskatchewan, S7N 5A2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.